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Abstract
Background: Adolescent and young adults (AYA) enrolment rates into cancer clinical trials (CCT) are the lowest of any
age group globally. As AYA have distinct biological, psychosocial and relational needs, we aimed to explore any unique
factors influencing their CCT decision-making process, including AYA-specific perceptions or attitudes towards CCT.
Methods: Qualitative interpretive descriptive methodology was used to explore AYA perceptions and decision-making
related to CCT. An analytic approach conducive to inductive imagining and exploratory questioning was used in order
to generate insights and interpret data.
Results: A total of 21 AYA were interviewed (median age: 31 (18–39)). Twelve (57%) participants had previously been
approached to participate in CCT. Major themes influencing trial enrolment decisions were: 1) severity of illness/urgency
for new treatment 2) side effect profile of investigational drug in the short and long term (e.g., impact on future quality of
life) 3) who approached patient for trial participation (oncologist vs. other) 4) additional information found on-line about
the trial and investigators, and 5) family, friends and peer group opinion regarding the CCT.
Conclusions: Several psychosocial and relational factors were identified as influencing AYA CCT decisions, some of which
are unique to this demographic. Specific strategies to address barriers to CCT and enable supportive decision-making
include: 1) involving family in decision-making and 2) helping AYA appreciate short- and long-term implications of trial
participation. Finally, exploring social networking and general education about CCT that AYA can independently access
may increase participation.
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Background
Adolescents and young adults (AYA), aged 15 to 39 years,
represent a unique subset of cancer patients. With over
70,000 AYAs diagnosed with cancer in the United States
annually, and 7600 diagnosed in Canada, this group repre-
sents approximately 4–5% of the North American adult
cancer population [1–3]. Lack of enrolment of AYA onto
cancer clinical trials (CCT) has been the focus of much
research [3, 4], predominantly related to investigating sys-
tem and regulatory barriers impacting access [5]. Examin-
ation of perceptions and attitudes towards CCT, also
known to impact trial participation, has been limited to
children/AYA in pediatric institutes [6–8], older adults [9,
10] and other marginalized populations [11], with few
studies focusing specifically on AYA treated in adult can-
cer centers.
CCT enrolment decisions are influenced by a variety
of factors including altruism, scientific benefit, recom-
mendations from medical personnel [12–14] and belief
that CCT offers the best treatment [15]. Potential bar-
riers to CCT enrolment include lack of trial awareness
[16], concern about side effects [10, 17], medical mis-
trust, including fear of being a guinea pig [11, 18],
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protocol stringency [10], belief that risks outweigh bene-
fits [14], concern regarding potential conflicts of interest
[19] and lack of trial availability or opportunity to par-
ticipate [16]. However, there is limited information about
the role that personal, socio-demographic characteristics,
and other factors might play in the acceptability of CCT
for AYA [7, 8, 20–25]. AYA CCT enrolment decisions
occur in the context of cognitive and emotional develop-
ment/growth, and self-identity maturation. As a result, it
is likely that unique psychosocial and relational factors
place additional stress on and influence their CCT
decision-making process [26]. Thus, this study aimed to
investigate AYA-specific perceptions or attitudes to-
wards CCT in an adult comprehensive cancer centre
and explore additional factors that may influence AYA
decision-making about CCT.
Methods
Study design
Qualitative interpretive descriptive methodology was
used [27]. This discovery-oriented approach allows for a
process whereby the researchers remain open to deriving
insights from the data in order to inform understandings
that answer questions relevant to clinical practice [28].
To do so, in-depth exploration of participants’ experi-
ences is sought with the aim of identifying thematic pat-
terns and commonalities, while simultaneously
accounting for individual variation [27]. The overarching
goal of interpretive description within this study was to
identify clinically relevant insights to support AYA deci-
sion making and enhance trial participation. The study
was conducted through the AYA Program at Princess
Margaret Cancer Centre, Canada [29, 30]. Research eth-
ics board approval was obtained prior to study com-
mencement (CAPCR 16-5376). Participants completed
written informed consent generally within 24 h of being
approached and prior to any study procedures. They
were reminded of their right to withdraw from study
participation at any time without affecting their care.
Sampling and recruitment
Eligibility criteria for participants included: patients aged
15 to 39 years upon cancer diagnosis; currently receiving
cancer care (active or in surveillance); and ability to en-
gage in an interview. Those unable to speak English, or
who had severe cognitive impairment that would limit
their participation were excluded. Patients with
leukemia, lymphoma, sarcoma, breast and testes cancer
were purposefully recruited with diverse backgrounds
with respect to age, clinical trial experience (accept,
decline, or neither) and treatment goals (metastatic or
disease free).
The principal investigators (AG (female, oncologist); JL
(male, oncologist)) who were part of the circle of care
identified potential participants during their regular out-
patient clinics and made initial contact with them regarding
the study. Those patients who were interested in learning
more were referred to two members of the study team (VF
(female, medical student); ST (female, nursing student)) with
whom the patients did not have any previous clinical rela-
tionship. These study team members provided a thorough
background of the study and patients were given as much
time as they needed to consider the study information and
provide informed consent or refusal to study participation.
Prior to the interview, participants were asked to
complete a demographics form. Participants were given
the option to conduct the interview at the current time,
or to schedule an interview time in the future. Patients
who participated in an interview were given a $10 gift
card for their time.
Data collection
Semi-structured face-to-face interviews were conducted
with each participant in a private setting at the hospital.
All participants individually engaged in the interview but
out of respect for the preferences and desires of some
AYA participants, a family member or friend was
allowed to be present during the interview to support
them. In these cases, the family member or friend
quietly observed the interview and only a few interjected
occasionally to give additional information that the par-
ticipant had missed about a certain event or in re-telling
a story. Most of the time the family member or friend
was silent.
An investigator-developed interview guide was created
to explore participants’ understanding of CCT, trial expe-
riences, factors that influence their decision-making about
trial enrolment, and AYA-specific perceptions or attitudes
towards CCT (see online Additional file 1: Table S1). The
guide was influenced by previous literature on the barriers
to CCT as experienced by other populations while allow-
ing for open-ended responses. The research team
reviewed the guide to ensure that questions were
all-encompassing and contained the necessary probes to
help facilitate informative responses. Participants were
conveyed a working definition of CCTs as defined by the
National Institute of Health [31]. Preliminary interviews
were conducted and analyzed to further refine the inter-
view guide in terms of applicability, ease of use, and effi-
ciency. Interviews were conducted with one of two
investigators (VF and ST) under the guidance of a mem-
ber of the research team (JB), who has extensive experi-
ence and training in conducting qualitative interviews.
Interviews were digitally recorded and transcribed verba-
tim by the researchers (VF and ST). The duration of the
interviews was variable (between 30 min to an hour and a
half). Transcripts were not returned to participants for
comment.
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Data analysis
Qualitative data analysis exists on a spectrum of data
transformation from description to interpretation [32].
Because our research aimed to inform clinical practice
change, an analytic approach closer to description was
used in order to generate insights and interpretation of
the interview data related to the research objective [27].
Two members of the research team (VF, ST) independ-
ently reviewed three interview transcripts with the intent
of developing “broad-based” codes (as opposed to
line-by-line coding) ([27], p., 160). These codes were re-
flective of those ideas, words or phrases identified as
relevant to the research aim. Broad-based or generic
codes allowed the researchers to remain open to the ut-
terances and meanings within the data so that they
might be further interrogated and allow for interpretive
thinking [27]. The researchers then met to compare and
contrast codes with a third member of the research team
(JB), and to establish inter-coder reliability. Consensus
was reached between team members (VF, ST, JB) on the
creation of new codes or the collapsing of data into
existing codes, and the building of detailed descriptions
to form an initial coding framework. The initial coding
framework was then applied independently by each re-
searcher (VF, ST, and JB) to four more transcripts. The
researchers (VF, ST, and JB) met again to discuss any
discrepancies in codes and in applying the initial coding
framework. Based on this discussion, the initial coding
framework was modified and distributed to the entire re-
search team for review. After review and approval, the
coding framework was applied by the researchers (VF,
ST) to the remaining transcripts. Codes were continually
compared between and among transcripts as the re-
searchers asked questions of the data such as “how im-
portant is this experience to AYA decision making?” and
“is this code qualitatively different than that code?” [28].
Further, potential relationships between identified codes
were explored in order to inform a cohesive and
clinically-relevant account of influences on AYA CCT
decision making [27].
The generation of major themes was guided by a for-
mal code repetition analysis whereby one member of the
research team used standard word processing software
(Microsoft Word) to count the number of times each
code was identified in the transcripts [33]. This exercise
served as a proxy for presumed importance of the ex-
perience. Major themes were identified as those codes,
ideas or experiences that had the most textual support
from multiple transcripts. To promote trustworthiness
of the findings [34], major themes were reviewed by the
entire research team and compared and contrasted with
previous literature on CCT participation in diverse pop-
ulations as well as the clinical experience of the
clinician-investigators. In addition, alternate perspectives
related to each theme were purposefully sought in order
to understand individual variation and to provide a more
comprehensive perspective of the collective experience.
Results
Twenty-three AYA were approached to participate in
the qualitative interviews between June and August,
2016. Of the 23 AYA approached, 21 consented to par-
ticipate. Eight AYA participant interviews included their
family member or friend. Participant characteristics are
shown in Table 1. The median age of participants was 31
(18-39). Twelve (57%) participants had been approached
to participate in CCT of which 10 (48%) had enrolled.
The majority of these participants (N = 9; 90%) had en-
rolled at the time of recurrence or during treatment for
metastatic disease.
Major themes
Major themes were categorized into positive, negative
and neutral influences on CCT participation as guided
by the research objective (Fig. 1). Positive influences en-
abled CCT participation, negative influences detracted
from CCT participation, and neutral influences either
had no effect on CCT participation or were described by
participants as supportive of their trial decision-making
process. The top five most frequent thematic influences
on AYA decision-making regarding CCT participation,
as identified in ≥90% of participant interviews, were: se-
verity of illness/urgency of treatment, influence of side
effects, recruitment method, additional information, and
opinion of others (Table 2).
Positive influences on CCT participation
Severity of illness/urgency of treatment Severity of ill-
ness/urgency of treatment was discussed by a majority of
those interviewed, and was identified by participants as a
positive influence on AYA’ willingness to participate in
CCT. Most AYA stated they would enrol in a trial out of
desperation if they had not responded effectively to the
standard treatment available and their disease was pro-
gressing or in an advanced stage. As reported by one
participant, age 38 (disease free, never been offered a
trial), “If I’ve been given a bad prognosis […] I would
probably be willing to participate [in a clinical trial], be-
cause maybe this new drug might help me”. Similarly, a
36 year-old participant (metastatic disease, currently en-
rolled on a clinical trial) stated, “I don’t have another op-
tion. Radiation is not an option, surgery is not an
option, so [a clinical trial] is what I’ve got”. Only one
participant said that they would have enough options
available so that CCT would not be worth their while.
Another participant did not mention severity of illness/
urgency as a concern.
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Negative influences on CCT participation
Trial side effects Influence of side effects was discussed
in most of the interviews. This theme referred to consid-
erations of how the experience of drug side effects
would influence CCT participation. Participants per-
ceived the possibility of trial side effects in diverse ways.
It could either act as a deterrent towards enrolling, or it
was described as having little to no effect on a patient’s
decision to enrol. Over half of participants stated they
would consider side effects prior to enrolling in a clinical
trial, while only a few participants said side effects were
not a major concern. Several participants stated they
had no other treatment options available so they would
try any treatment regardless of side effects; one
participant was concerned only if side effects had a high
probability of occurrence. Other participants believed
that CCT offered the best chance of cure so they would
endure any side effects, or they downplayed the signifi-
cance of side effects, perceiving they would be easily
treated while on trial. Approximately half of participants
stated that long-term or severe side effects were quite
concerning and that they would need to thoroughly con-
sider their participation prior to enrolment. These par-
ticipants stated the need to weigh the potential for side
effects to impact their future quality of life (QOL)
against the therapeutic gains from the trial. One 23 year--
old participant (metastatic disease, currently enrolled on
a trial) mentioned that, “If [the side effects were] some-
thing like numbness [..] I would still go through with
Table 1 Participant Characteristics
Total participants (n, %) 21
Age, Median (Range) 31 (18-39)
Gender Male 10 (48)
Female 11 (52)
Cancer Diagnosis Testes 3 (14)
Leukemia 3 (14)
Lymphoma 6 (29)
Breast 3 (14)
Sarcoma 6 (29)
Previous Trial Involvement Approached regarding CCT 12 (57)
Phase I 2 (10)
Phase I/II 3 (14)
Phase II 3 (14)
Phase III 4 (19)
Not Approached regarding CCT 9 (43)
Enrolled on CCT 10 (48)
Enrolled at time of diagnosis 1 (5)
Enrolled at time of recurrence or during
treatment for metastatic disease.
9 (43)
English as first language Yes 18 (86)
No 3 (14)
Student and employment status Currently Working 6 (29)
Working prior to diagnosis 13 (62)
Currently at School 3 (14)
Completed university degree Yes 14 (67)
No 7 (33)
Children Yes 9 (43)
No 12 (57)
Mean no. of dependent children 1.3
Relationship Status Single 4 (19)
In a Relationship 8 (38)
Married 9 (43)
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[the clinical trial] because my options are getting smaller
as more regimens are not working for me. But if it was
something pretty serious I would explore my options be-
sides this”. When separated by stage of disease, five of
six patients without active disease shared concerns re-
garding long-term side effects from CCT as opposed to
eight of 15 for those with metastatic disease.
Neutral influences on CCT participation
Recruitment method Recruitment method was de-
scribed in all of the interviews. This was a general theme
used to encompass descriptions of how trial personnel
had approached AYA patients about trial participation,
and reflections on how this might influence their
decision to enrol or not. This theme included partici-
pants’ preferred method of being approached about a
trial (through email, in-person, or over the phone) along
with the timing of approach and from whom they would
prefer to hear about a clinical trial for the first time (e.g.
from an oncologist, nurse or member of the research
team).
More than half of participants said they preferred their
oncologist to initiate a trial conversation, while the
remaining were ambivalent as long as they had the ne-
cessary information to answer any questions they might
have about the trial. There was no consensus regarding
the preferred timing of being offered a trial or how re-
cruitment should be initiated, although some partici-
pants thought they should only be approached about a
Fig. 1 A total of 35 themes were identified as influencing AYA patient decisions regarding enrollment in CCT. These themes were classified as
either positive, negative or neutral influencers affecting AYA clinical trial enrollment
Table 2 Five prevalent themes influencing AYA decision making were identified in ≥90% of participants
Theme
Classification
Theme Example
Positive Severity of illness/urgency (95%) “I brought up side effects a few times, but if there weren’t
really any options or the current options weren’t working
and my team was at a loss of what to do. I don’t see that
I would have a choice.”
Negative Concern about side effects (90%) “Yes, it would. Permanent side effects? No thanks. The side
effects I’ve already been having with chemo are harsh enough...
definitely side effects would be huge thing”
Neutral Recruitment method (100%) “I was approached very nicely and academically and they gave
me the right information. I was able to meet a lot of different
professionals working on the trial and felt confident because I
got a lot of different perspectives by different teams.”
Additional information (95%) “I like that I was able to talk about it with my doctor… I know
ultimately I make most of the decisions for myself but I hold him
in very high regard.”
Opinion of others (100%) “My friends and family are very informed and aware of what is
going on with me. Always want to come to the hospital and
they all do their own research…It’s great, I am very supported.”
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trial if their standard treatment was not working. Add-
itionally, participants believed an offer of trial participa-
tion should not be extended to patients who had just
been diagnosed, thinking these patients would be too
overwhelmed or not in a stable state of mind to receive
further information about clinical trials.
Additional information
Seeking additional information was discussed in most of
the interviews. This theme related to the role additional
information played in participants’ decisions about CCT
participation. Almost all participants reported conduct-
ing online research for published studies or gathering
more information about the protocol and study investi-
gators. A few participants sought a second opinion from
an oncologist who was not their primary physician for
more information or to explore additional treatment op-
tions. Two participants said they would try to contact
previous clinical trial participants to obtain their per-
spectives and experiences in order to inform their deci-
sion making.
Opinions of others
Opinions of others was described in all of the interviews.
This theme related to the ways in which the opinions of
family members or friends influenced the clinical trial
decision. The majority of participants said that family
would be involved in the clinical trial decision-making
process by helping them to make a decision, supporting
their search for more information about the trial, or
helping them to stay informed about the clinical trial
process throughout recruitment and study participation.
Only one participant excluded family in the clinical trial
decision. This 28 year-old female explained that she
made the decision to enrol in a CCT immediately after
the doctor offered the option due to its high success
rate. She stated that her only other treatment options
would not offer a chance for a full recovery, so the CCT
was the best option. Two participants stated that family
pressured them with regards to clinical trial participation
as opposed to simply offering their opinion. A 21 year--
old patient (metastatic disease, had previous clinical trial
experience) explained how her father hurried her deci-
sion and encouraged her to participate based on altruis-
tic reasons. “[From] my dad, I think it was a bit more of
pressure to join the trial […]. If I were alone I would’ve
thought about it for a little bit longer, and maybe I
wouldn’t have done it”. She stated her father “pushed”
her into enrolling in a clinical trial, as it would be “great
for research” and “improve the outcome for others.”
Discussion
As AYA enrolment rates into CCT are the lowest of any
age group globally, a major focus of recent research is to
understand the barriers to trial participation. In this
study of AYA at a large adult comprehensive cancer
centre, several overarching themes were identified re-
garding psychosocial and relational factors influencing
AYA CCT decisions, some of which are unique to this
demographic.
Many AYA were concerned about both short- and
long-term side effects and outcomes of CCT on their fu-
ture QOL. Of note, we did not specifically probe partici-
pants as to whether the toxicity concerns were in
addition to standard of care drugs (which are often the
comparator arm of many CCT) that often carry their
own side effect profile. Although drug side effects are a
factor in adult cancer patient trial decisions [10, 35], the
priority AYA place on longer-term implications appear
to be unique to this cohort. Hope for longevity likely in-
fluences AYA’ concerns about the long-term impacts of
an investigational agent on future QOL. Whereas older
adults may perceive themselves as having lived a signifi-
cant proportion of their lives, and focus on giving back
to others through trial participation [12–24], our find-
ings suggest AYA’ future-oriented considerations may be
closely intertwined with stage of disease and consider-
ations of what is best for one’s self in making a trial deci-
sion. This emergent finding may have important
implications for how trials might generally be promoted
or discussed with AYA. For example, public advertise-
ments emphasizing the benefit of helping others may
not be as relevant for AYA [36].
Another central theme we identified is method of re-
cruitment. Participants indicated they would not want to
be approached for a CCT if they had just been diagnosed
or were otherwise overwhelmed with their treatment
course. Distress or uncertainty has been identified as a
detractor of decision-making ability in a wide range of
treatment contexts [37]. Previous literature has demon-
strated that adolescents between the ages of 14-18 years
may have greater difficulty self-regulating their emotions
in response to a life-threatening illness [38], which may
make managing their distress in the context of trial
decision-making even more challenging. Our findings
suggest an important role for professionals to respond to
AYA psychological needs, and a CCT recruitment ap-
proach that encourages their capacities to make an in-
formed trial decision. For example, approaching AYA
about a study using simplified age-appropriate language,
acknowledging their emotions and offering further sup-
port/resources tailored to their situation, and addressing
any practical barriers to CCT participation (e.g., child
care, transportation). In this study, AYA preferred their
oncologist to introduce them to a trial rather than an in-
dependent trial nurse. As such, educating oncologists in
adult cancer services of the unique needs of AYAs may
aid in recruitment onto CCT.
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Finally, family opinion had a profound influence on
CCT decision-making. The majority of AYA involved
their family in the CCT decision-making process, and
perceived their role as supportive in terms of helping
them to seek and interpret trial information and make a
decision. However, some participants experienced family
as an undue influence, particularly when loved ones
undermined their autonomy or capacity to fully reflect
on their values and determine a course of action.
Shared decision-making is a care delivery model en-
couraged by the American and Canadian Pediatric Soci-
eties [39, 40]. A recent review identified that adolescents
and parents prefer partnership and cooperation as op-
posed to complete independence in decision making
about cancer treatments, clinical research, and
end-of-life decisions [41]. In fulfilling our ethical and
professional obligations, it should not be assumed that
every AYA wants to involve their family in decision mak-
ing to the same extent or in the same way. AYA encom-
pass a wide age range including adolescents aged 15 to
mature adults aged 39. For those who are capable, pro-
viders should seek direction from AYA about who con-
stitutes ‘family’, and the level of involvement they prefer
their family to have [39]. Furthermore, AYA retain the
moral and oftentimes legal right to decline CCT partici-
pation. In a partnership model, AYA should not be pres-
sured to accept CCT participation against their will or
solely on the basis of their parents’ wishes.
A Cochrane review identified interventions to promote
participation in shared medical decision making for chil-
dren with cancer [42]. These interventions included
healthcare professional training, and implementation of
patient-mediated interventions including decision aids.
Although not specifically targeted to AYA, some of these
strategies may be tailored for AYA and evaluated within
the clinical research setting. Other communication strat-
egies to improve collaboration between physicians, pa-
tients and family may also be employed with a goal of
evaluating these strategies.
Many AYA used the internet as a primary source for
obtaining additional trial information. Current trial data-
bases meant to provide information to patients could be
enhanced for AYA [43]. For example, these websites
could explore the integration of trial information with
online media, social networking sites and online forums
as a space for CCT education to enhance AYA know-
ledge about trials and potentially increase accrual.
We acknowledge several limitations to this study. First,
AYA include a wide age range and developmental stages.
Given the sample heterogeneity and size, we were unable
to explore emergent themes in greater depth, stratified
by age, developmental milestones, and clinical trial deci-
sion. This is particularly important as 18 was the lowest
age range we investigated and one could expect that
different themes would be identified in younger versus
older AYAs. Not unexpectedly, stage of disease appeared
to have interplay with CCT acceptability. As a follow on
from this study, we are currently investigating CCT de-
cision making stratified per age group and its interplay
with relevant psychosocial, relational influences and
stage of disease. In addition, this study was limited to
understanding the experiences of AYA who were receiv-
ing care at one adult urban comprehensive cancer
centre. Future research could involve AYA who are re-
ceiving care at community-based cancer settings.
Conclusion
To our knowledge, this is one of only a few studies
examining CCT perceptions of AYA at an adult cancer
center aimed at identifying barriers to trial enrolment
and enabling supportive decision-making. Several over-
arching themes regarding important factors and contexts
that influence AYA CCT decisions were identified. Spe-
cific strategies may include providing opportunity for pa-
tients to involve family in decision-making and assisting
AYA in appreciating short- and long-term implications
of CCT participation. Finally, exploring social network-
ing/online forums and general education about CCT
that AYA can independently access, may increase their
willingness to participate.
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